InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,615.35
(
0.55%
)
US TECH 100
19,804.00
(
0.64%
)
Dow Jones
40,000.90
(
0.62%
)
Brent Oil
84.57
(
0.00%
)
Bitcoin
58,693.02
(
1.39%
)
Post# of 19309
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 831
Posts 120032
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: oldacct post# 6028

Monday, 12/10/2007 1:26:05 PM

Monday, December 10, 2007 1:26:05 PM

Post# of 19309
>I thought the significance of Kamada's orphan drug status was the aerosol delivery.<

It is. However, GTC hopes to eventually have its own inhaled AAT product and hence being able to break Kamada’s orphan status is relevant. From the 3Q07 CC (#msg-24216158):

“…our program in alpha 1-antitrypsin is continuing to move ahead steadily… The future may lie in the development of a pulmonary delivery of this product which, in turn, may open up the opportunity of a broader range of clinical indications in which elastase destruction of the lung and resulting inflammatory conditions play a part.”

Regards, Dew

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up